I stumbled up this link showing that Resverlogix presented two abstracts at Vascular Discovery conference, May 10-12, 2018. I'm surprised that I need to be the one to find and post this and that the company didn't promote their attendance or presentation.  Some of the info in the abstracts is old, some of it is new. A couple new things jumped out to me. Follow the link for the full abstracts.

Abstract 256 is entitled "Apabetalone (RVX-208) Reduces Pathologic Cell-Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and Mouse Aorta." I think this is the first time they've discussed a mouse diet-induced obesity (DIO) model treated with apabetalone. In this DIO model, apabetalone "downregulated aortic adhesion markers (Eselectin and ICAM) and markers of infiltrating immune cells (CCR2 and CD11b)." Another good validation that one of apabetalone's effects is to reduce vascular inflammation.

Abstract 669 is entitled "Apabetalone (rvx-208) Decreases Risk of Major Adverse Cardiovascular Events in Diabetes Mellitus Patients with Cvd by Attenuating Monocyte Adhesion to Endothelial Cells." They show that apabetalone inhibits the transcription of a transcription factor called farnesoid-x-receptor (FXR) in primary human hepatocytes. They had previously shown that apabetalone blocks the activity of the dietary metabolite trimethyl-amine oxide (TMAO). Now they also show that the expression of flavin mono-oxygenase-3 (FMO3), an FXR target that catalyzes TMAO production, is inhibited by apabetalone presumably via an indirect effect of inhibiting FXR expression. They state that within 6 hours of apabetalone treatment they achieved >80% suppression of FXR mRNA and protein. FXR is an important transcription factor for bile acid, glucose and lipid metabolism. I have a feeling this won't be the last time we hear about FXR and apabetalone.

BearDownAZ